AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre
From the article
AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & Co.’s chronic obstructive pulmonary disease drug Ohtuvayre.
Continue reading on Fierce BiotechYou might also wanna read
AZ pays $200m upfront for Sino Bio COPD drug
pharmaphorum·14h ago
Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal
The Daily Upside·12d ago
GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million
GSK·17y ago
LG Chem partners with China's OTR to develop cancer drugs
The Korea Herald·23h ago
LG Chem Partners with Chinese Biotech to Develop Cancer Drugs
Seoul Economic Daily·1d ago
Alibaba to pay $600 million to settle U.S. lawsuit over illegal drug sales on its platforms
Alibaba has agreed to pay $600 million to settle a lawsuit with the U.S. federal government over allegations that the company facilitated th
fox5dc.com·4d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.